NCT03567655 is a Phase 2 clinical trial of Farlutal tab. 500mg/ Pfizer in Endometrial Cancer, sponsored by Asan Medical Center.

Who is sponsoring NCT03567655?

NCT03567655 is sponsored by Asan Medical Center.

What drugs are being tested in NCT03567655?

Interventions in NCT03567655: Farlutal tab. 500mg/ Pfizer.

What condition does NCT03567655 study?

NCT03567655 studies Endometrial Cancer.

Is NCT03567655 still recruiting?

NCT03567655 is currently status unknown. Last updated 26 June 2018.

Last reviewed 2018-06-26 · How we verify

NCT03567655

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fertility-sparing Management Using High-dose Oral Progestin in Young Women With Endometrial Cancer

Status unknown Phase 2 Last updated 26 June 2018

What this trial tests

Phase 2 trial testing Farlutal tab. 500mg/ Pfizer in Endometrial Cancer in 41 participants. Status unknown.

Timeline

15 July 2018

Primary endpoint
31 October 2022

30 November 2022

Quick facts

Lead sponsor	Asan Medical Center
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	41
Start date	15 July 2018
Primary completion	31 October 2022
Estimated completion	30 November 2022
Sites	1 location across South Korea

Drugs / interventions tested

Farlutal tab. 500mg/ Pfizer — full drug profile →

Conditions studied

Endometrial Cancer — all drugs for Endometrial Cancer →

Sponsor

Asan Medical Center

Who can join

Adults 20 to 40, female only, with Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This registry aims to evaluate the efficacy of using high-dose oral progestin in young women with stage I endometrial adenocarcinoma with grade 2 differentiation or superficial myometrial invasion as a fertility-sparing management.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The Perspectives of Fertility Preservation in Women with Endometrial Cancer.
Knez J, Al Mahdawi L, Takač I, Sobočan M. · · 2021 · cited 22× · PMID 33546293 · DOI 10.3390/cancers13040602
Improving response to progestin treatment of low-grade endometrial cancer.
Baxter E, Brennan DJ, McAlpine JN, Mueller JJ, et al · · 2020 · cited 22× · PMID 32381512 · DOI 10.1136/ijgc-2020-001309
From the Beginning of the Korean Gynecologic Oncology Group to the Present and Next Steps.
Min KJ, Kim NK, Song JY, Choi MC, et al · · 2024 · cited 2× · PMID 39410040 · DOI 10.3390/cancers16193422

Verify or expand the search:

Other recruiting trials for Endometrial Cancer

Currently open trials in the same condition.

NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
NCT07382583 — Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the P · recruiting
NCT07377734 — Intrauterine Injection of Type III Collage in FST of EC/AEH · Phase 2 · recruiting
NCT07319429 — Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification · Phase 2, PHASE3 · recruiting
NCT07397624 — Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer · recruiting

Other Asan Medical Center trials

Trials by the same sponsor.

NCT07530393 — Blood Viscosity and Outcomes After Elective Craniotomy · not yet recruiting
NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07382505 — Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cerv · not yet recruiting
NCT07489092 — Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge · NA · recruiting
NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03567655 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Asan Medical Center
Last refreshed: 26 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03567655.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing